Items Tagged ‘RESPONSE’

December 27, 2017

Long Term Follow Up Shows Durability of Jakafi® Response in Patients with Polycythemia Vera


CancerConnect News: Jakafi® (ruxolitinib) was initially reported to help patients with polycythemia vera (PV) maintain hematocrit control more effectively than the best available therapy at the 56th American Hematology Society Annual Meeting in 2014.1,2 Now with a full 4 years of follow-up from this trial the benefit of Jakafi® continues to be confirmed. Results recently presented […]

View full entry

Tags: clinical trial, Incyte, jakafi, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, RESPONSE, ruxolitinib